Ironwood Pharmaceuticals Inc (NAS:IRWD)
$ 4.45 -0.14 (-3.05%) Market Cap: 712.13 Mil Enterprise Value: 1.26 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 54/100

Ironwood Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 12, 2019 / 11:10PM GMT
Release Date Price: $11.35 (+2.16%)
Unidentified Analyst

It's my pleasure to introduce you to Mark Mallon, CEO of Ironwood.

Mark Mallon
Ironwood Pharmaceuticals, Inc. - CEO & Director

Thanks, Mark, and thanks to Crédit Suisse to -- for giving us a little bit of opportunity to talk about what we're doing at Ironwood Pharmaceuticals.

I'm really pleased to have the opportunity to tell you about the progress that we made since we launched the new Ironwood on April 1 of this year as a GI-focused health care company. As always, this presentation will include some forward-looking statements. This is the usual disclaimer associated with that.

So when we launched the new Ironwood as a GI-focused company, we set out 3, I think, simple and clear objectives that will really deliver value to patients and to shareholders. First is to accelerate LINZESS growth. The second is to advance our late-stage GI pipeline. And then the third is to begin delivering profits from day 1 in 2019. And what I want to do over the next few minutes is to actually take you through what we've done. I think we've

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot